Overview

This trial is active, not recruiting.

Condition graft versus host disease
Treatments lactobacillus rhamnosus gg, laboratory biomarker analysis
Sponsor Rutgers, The State University of New Jersey
Collaborator Rutgers Cancer Institute of New Jersey
Start date February 2013
End date February 2017
Trial size 33 participants
Trial identifier NCT02144701, 021202, NCI-2013-00094, P30CA072720, Pro2012001625

Summary

This randomized pilot clinical trial studies Lactobacillus rhamnosus GG in reducing incidence of graft-versus-host disease in patients who have undergone donor stem cell transplant. Lactobacillus rhamnosus GG may be effective at preventing for graft-versus-host disease caused by a donor stem cell transplant.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose supportive care
Arm
(Experimental)
Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
lactobacillus rhamnosus gg Culturelle
Given PO
laboratory biomarker analysis
Correlative studies
(No Intervention)
Patients receive no intervention.

Primary Outcomes

Measure
Rate of grade 1 upper GI and/or 2-4 lower GI aGVHD assessed using CIBMTR scoring
time frame: Baseline
Rate of grade 1 upper GI and/or 2-4 lower GI aGVHD assessed using CIBMTR scoring
time frame: 1 month
Rate of grade 1 upper GI and/or 2-4 lower GI aGVHD assessed using CIBMTR scoring
time frame: 3 months
Rate of grade 1 upper GI and/or 2-4 lower GI aGVHD assessed using CIBMTR scoring
time frame: 6 months
Rate of grade 1 upper GI and/or 2-4 lower GI aGVHD assessed using CIBMTR scoring
time frame: 9 months
Rate of grade 1 upper GI and/or 2-4 lower GI aGVHD assessed using CIBMTR scoring
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Able to sign informed consent - Undergoing allogeneic HSCT from a related or unrelated donor - Hematopoietic engraftment as evidenced by recovery of the absolute neutrophil count to greater than 500/mm^3 for > 3 days without filgrastim (G-CSF) support and within 40 days of transplant (i.e. complete blood counts [CBCs] obtained 3 or more days apart while off of G-CSF must demonstrate an absolute neutrophil count > 500/mm^3); if absolute neutropenia is not achieved due to a non-myeloablative transplant, the patient can be enrolled on day +21 to +40 - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 Exclusion Criteria: - Evidence of GVHD at the time of enrollment as assessed clinically - Serum creatinine greater than 3.0 - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal - Total bilirubin greater than 2 times upper limit of normal - Prior use of probiotics within 3 months prior to enrollment - Inability to take medications by mouth - Prior history of inflammatory bowel disease or other chronic diarrheal illness - Prior history of hypersensitivity to milk proteins - Active Clostridium difficile infection or on prophylactic or tapering antibiotics for Clostridium difficile infection

Additional Information

Official title A Randomized Trial Testing a Probiotic Enteric Regimen for Easing Complications of Transplant (Randomized PERFECT Trial)
Principal investigator Roger Strair
Description PRIMARY OBJECTIVES: I. To determine if hematopoietic stem cell transplant (HSCT) patients treated with a probiotic (Lactobacillus GG [Lactobacillus rhamnosus GG])-containing diet compared to those not assigned to receive probiotic have a lower incidence of grade 1 upper gastrointestinal (GI) or grade 2-4 lower GI acute graft-versus-host disease (GVHD) (aGVHD) using Center for International Blood and Marrow Transplant Research (CIBMTR) scoring than those not prescribed a probiotic. II. To determine if HSCT patients treated with a probiotic-containing diet compared to those not assigned to receive a probiotic have a: a) lower rate of organ-specific acute aGVHD (intestinal tract, skin, liver); b) lower rate of moderate or severe chronic GVHD (National Institutes of Health [NIH] consensus scoring) at 6 months and 1 year post transplant; c) shorter duration of immunosuppressive therapy (normalized for age and degree of human leukocyte antigen [HLA] match); d) lower rate of bacterial and/or opportunistic infection. SECONDARY OBJECTIVES: I. To determine if allogeneic hematopoietic stem cell patients treated with a probiotic compared to those not assigned to receive a probiotic have differences in: a) composition and proportion of the major gut bacterial phylotypes in stool (to be analyzed for changes pre- and post-initiation of probiotics and for association with development of aGVHD); b) measures of inflammation as assessed by cytokine or receptor production (interleukin [IL]-6, IL-8, tumor necrosis factor [TNF]-alpha, TNF-receptor 1, interferon-gamma, IL-2R, IL-10); c) qualitative measures of immune reconstitution as determined by sequential measurements of conventional T cells, regulatory T regulatory, B cells and natural killer (NK) cells; d) antibody class/subclass production; e) biomarkers associated with GVHD-elafin, regenerating islet-derived 3 alpha (Reg3a), suppressor of tumorigenicity-2 (ST2), hepatocyte growth factor (HGF); and/or urinary tryptophan metabolites; f) markers of gut barrier function including blood levels of endotoxin and microbial deoxyribonucleic acid (DNA). OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive Lactobacillus rhamnosus GG orally (PO) once daily (QD) for 1 year. ARM II: Patients receive no intervention.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Rutgers, The State University of New Jersey.
Location data was received from the National Cancer Institute and was last updated in November 2016.